ProKidney's autologous cell therapy rilparencel demonstrated a significant reduction in kidney function decline by 78% in one cohort of diabetic chronic kidney disease patients. Another cohort receiving a single injection showed a 50% improvement that was not statistically significant. The company is preparing for Phase 3 trials based on these data, using eGFR slope as a surrogate endpoint for regulatory discussion. The therapy aims to regenerate damaged kidney tissue by integrating progenitor cells to improve organ function.